

1 Finally, we studied the tactics of
2 polluting industries and their shameful legacy of
3 attempting undermine science, whether it was the
4 tobacco industry or the lead industry, we learned
5 about the deliberate, expensive, decades-long
6 campaigns to protect corporate profits, and
7 meanwhile people were literally dying as a result.
8 This is an old story. We've heard it before, and
9 we're hearing that story again. Public health
10 professionals are trained to recognize history and
11 call it out, which is what we are doing today.

12 This proposal is an excuse to hamstring
13 researchers to weaken public health protections,
14 and to pad the profits of polluting industries.
15 As a public health professional, as a mother, and
16 on behalf of the 1 million members of Moms Clean
17 Air Force, I strongly urge the EPA to stop this
18 proposal for the health and safety of all
19 Americans. Thank you.

20 MR. TEICHMAN: Thank you.

21 MS. GOTTLIEB: Good morning. My name is
22 Barbara Gottlieb, G-O-T-T-L-I-E-B. I'm the

1 Director for Environment and Health at Physicians
2 for Social Responsibility.

3 On behalf of our 33 members, I'm here to
4 express our opposition to the proposed rule --
5 "Strengthening Transparency in Regulatory
6 Science."

7 The U.S. EPA plays a critical role in
8 keeping our nation and our families safe from
9 environmental exposures that can cause illness and
10 death. We thank you for that - and we count on you
11 for it. Because your role is vital to our health
12 and well-being, the nation relies on you to
13 formulate and enforce the most effective
14 protections possible, based on the best available
15 science. The medical and scientific studies that
16 underlie the EPA's decisions must be objective,
17 vetted, and present a full and accurate assessment
18 of the threats to health posed by the pollutants
19 under study.

20 To provide those full and accurate
21 assessments, studies need to relate exposure
22 levels to actual health outcomes in real human

1 beings, and to amass large data bases so that
2 researchers can draw valid conclusions.

3 In order to have reliable data and large
4 sample sizes, researchers frequently study the
5 records of patients treated in hospitals. Hospital
6 records, of course, include personal identifiers,
7 and disclosure of those identifiers would violate
8 privacy and confidentiality laws. Thus, the best
9 available data for many health studies cannot be -
10 in the literal sense -fully and openly shared.

11 However, to refuse to consider scientific
12 studies simply because they include personal
13 identifiers -- would be a great mistake, nor is it
14 necessary. Reviewers wanting to reproduce a study
15 in order to validate it can arrange to have
16 confidential access to key data. Furthermore,
17 scientists can assess the merits of published
18 research without seeing its data by considering
19 such published features as the study's research
20 design, the methods used for data collection and
21 analysis, and comparison with previous results.

22 In any case, to exclude credible peer-

1 reviewed scientific studies because the personal
2 identifiers cannot be released under the law, is
3 to exclude from the EPA's consideration many
4 important and valid studies. This would greatly
5 hamper our ability, your ability, to understand
6 the impacts of serious, even deadly, pollutants.

7 I'd like to cite, as example, three
8 studies that could be lost to consideration under
9 the proposed rule, on a topic I haven't heard
10 referred to today. These studies reveal
11 statistical correlations between exposure to
12 emissions from fracturing, or fracking, for oil
13 and gas, and serious health outcomes.

14 So the first is a study by University of
15 Pennsylvania and Columbia University researchers
16 and published in 2015 in the journal, PLoS ONE,
17 found that drilling and fracking activity in
18 Pennsylvania was associated with increased rates
19 of hospitalization for cardiology, neurology,
20 cancer, skin conditions, and urological problems.

21 In communities with the most wells, the
22 rate of cardiology hospitalizations was 27 percent

1 higher than in control communities with no
2 fracking. These findings are obviously of great
3 concern; we would not want them to be lost to the
4 EPA as you consider regulation of fracking related
5 emissions.

6 Yet because the data includes such things
7 as patients' names, diagnoses, addresses, and zip
8 codes, this valuable study could be, under the
9 proposed rule, excluded from EPA consideration.

10 Another study conducted in Pennsylvania
11 between 2005 and 2012, found that living near
12 fracking operations significantly increases asthma
13 attacks. This study was conducted by researchers
14 at Johns Hopkins University and it was based on a
15 study of 35,000 medical records of people with
16 asthma. This is just the sort of study that we
17 want EPA to base its health-protective regulations
18 on: a robust database conducted by researchers at
19 a respected institution and published, as this one
20 was, in the Journal of the American Medical
21 Association Internal Medicine.

22 Yet should the proposed rule be adopted,

1 this study could be disallowed because its 35,000
2 medical records cannot easily be scrubbed of
3 personal identifiers.

4 Third example, a study by the Johns
5 Hopkins Bloomberg School of Public Health and
6 other researchers, used data from the Geisinger
7 Health System on over 9,000 pregnant women and
8 their over 10,000 newborns between January 2009
9 and January 2013. The researchers found that the
10 pregnant women who live near active fracking
11 operations in Pennsylvania were at a 40 percent
12 increased risk of giving birth prematurely.
13 Premature birth is the leading cause of infant
14 death in this country.

15 So we're talking about data that indicate
16 that fracking operations could put newborn babies
17 at risk of death. This was a study published in
18 the peer review journal, Epidemiology.

19 Our families should have the benefit of
20 these studies and many more that might be
21 disregarded under the proposed rule. To exclude
22 them would be to weaken the scientific record and

1 undercut an accuracy and strength of EPA's
2 regulatory process, and to endanger human health.

3 For that reason, Physicians for Social
4 Responsibility opposes the proposed rule. Thank
5 you.

6 MR. ROBBINS: Thank you.

7 MS. HALL: Would Speaker Number 36,
8 Lyndsay Alexander, and Speaker Number 37, Laura
9 Bender, come up to the speaker's table.

10 And would Speaker Number 38, Liz
11 Borkowski, and Speaker Number 39, Janice Nolen,
12 take your seat at the on-deck chairs.

13 MS. ALEXANDER: Good morning. My name is
14 Lyndsay Alexander, A-L-E-X-A-N-D-E-R. I direct
15 the National Health Year Campaign at the American
16 Lung Association. I am also the mother of a
17 thriving toddler, who like all children, deserves
18 healthy air to breath, and safe water to drink
19 that won't make him sick or die prematurely.

20 I am here to ask EPA to withdraw this
21 proposed rule because I'm very concerned that
22 rather than foster transparency in regulatory

1 science, this rule promotes a callous effort to
2 suppress and censor the science used to inform EPA
3 policy to the detriment of millions of Americans'
4 health and well-being.

5 EPA's ability to effectively fulfill its
6 mission and protect public health from dangers,
7 such as air pollution, hinges on the ability of
8 its scientists to first evaluate the best
9 available scientific evidence of the health
10 threats of air pollution. Recognizing that
11 scientists' understanding of the relationship
12 between air pollution and public health would
13 continue to evolve, congress wisely required EPA
14 to review the latest evidence and revise air
15 pollution limits for six key pollutants every five
16 years. And then to work with states to reduce
17 pollution to meet the limit.

18 While more work remains, this basic
19 approach has worked exceedingly well at reducing
20 ambient air pollution, saving lives, and improving
21 health by preventing asthma attacks, heart
22 attacks, and many other negative health outcomes

1 from air pollution.

2 This proposed rule would require EPA to
3 exclude many of the best available peer-reviewed
4 and rigorously scrutinized studies from
5 consideration during decision-making, such as its
6 upcoming air quality standard reviews for ozone
7 and particulate matter.

8 Excluding studies for which raw data are
9 not available due to concerns over patient
10 confidentiality, or which do not meet vague
11 standard of reproducibility because studies were
12 conducted over long periods of time, or connected
13 to real world events beyond the control of
14 researchers, would greatly narrow the body of
15 evidence and the quality of the information that
16 EPA can consider. This would undoubtedly lead to
17 weaker protections and EPA's ability to estimate
18 the true threats of air pollution on human health,
19 and the benefits of reducing pollution, and thus
20 result in weaker air pollution limits.

21 In 1993, researchers at Harvard
22 University published a landmark air pollution

1 study, showing that particulate matter air
2 pollution was linked to premature death. The
3 Harvard Six Cities Study, as it is known, tracked
4 the health of 8,111 adults, and 14,000 children in
5 six small cities in the United States, beginning
6 in the 1970s.

7 This study found that people in cities
8 with cleaner air were living two to three years
9 longer than those living in cities with dirtier
10 air. Residents of Steubenville, Ohio, the city
11 with the dirtiest air, were 26 percent more likely
12 to die prematurely than were citizens of Portage,
13 Wisconsin, the city with the cleanest air.

14 What surprised researchers was that the
15 culprit was particulate matter, not sulfur-
16 dioxide, as they had thought. This was a very
17 important scientific discovery. This study, and
18 countless others since, have helped EPA to
19 understand that particle pollution in the air we
20 breathe, resulting from activities such as burning
21 coal for electricity, or diesel exhaust from
22 vehicles, harms human health in profound ways in

1 communities across the nation and has paved the
2 way for stronger air pollution limits designed to
3 protect public health.

4 But the data for the Harvard Six Cities
5 Study are not publicly available, and the study
6 was conducted over a long period of time that make
7 it very difficult to reproduce. Industry, and
8 their allies in congress previously challenged the
9 findings of this study and other similarly
10 important studies. Instead of blocking the
11 studies, as this proposal would do, EPA took a
12 logical step and referred them to an independent
13 third-party, the Health Effects Institute, for a
14 deep dive review.

15 There, autonomous reviewers examined the
16 data and developed a report that confirmed their
17 original findings. Other research has since
18 confirmed similar findings, including some studies
19 that use publicly available data sets. Critically
20 important studies, such as the Harvard Six Cities
21 Study would likely be excluded under this proposal
22 to the detriment of health protections. This

1 proposal would also affect other protections
2 currently in place, such as limits on certain
3 toxic air emissions from tail pipes and smoke
4 stacks, and information on the health effects of
5 many of these; more than 150 chemicals come from
6 older studies built on confidential patient or
7 private business data that cannot be made public.

8 This could -- this proposal could also
9 cull the use of research that includes
10 confidential business information or older studies
11 that has data stored on older technology that
12 can't be recovered, just to name two other
13 limitations.

14 Thank you for the opportunity to speak
15 today. The American Lung Association will submit
16 more detailed written comments.

17 MR. ROBBINS: Thank you.

18 MS. BENDER: Good morning. My name is
19 Laura Bender, L-A-U-R-A B-E-N-D-E-R, and I'm the
20 National Director of Advocacy of the American Lung
21 Association's Healthy Air Campaign.

22 The lung association's mission is to save

1 lives by improving lung health and preventing lung
2 disease. And as you know, we strongly oppose
3 EPA's so-called, "Strengthening Transparency in
4 Regulatory Science," proposal.

5 Today you've heard from many
6 representatives at the public health and medical
7 community about the ways this proposal would
8 undermine human health. I'd like to take a few
9 minutes to highlight the Lung Association's
10 concerns about the lack of transparency in EPA's
11 work on this rule.

12 The administration has attempted to rush
13 this rule forward at every turn, consistently
14 sacrificing expert analysis and public health
15 along the way. This is a sweeping proposal that
16 will impact a wide range of public health
17 safeguards, essentially affecting every future
18 decision at EPA based on science. And yet, EPA's
19 process in issuing it has been haphazard, rushed,
20 and anything but transparent.

21 First, back in April, then Administrator
22 Scott Pruitt, prematurely announced the proposal

1 while it was still undergoing interagency review
2 at the White House Office of Management and
3 Budget. Then, when media inquired about this
4 discrepancy, OMB actually backdated the clearance
5 by several days. This means that OMB only
6 reviewed the proposal for 48 hours. That's a
7 staggering tight timeline for such a sweeping
8 rule.

9 In a similar vein, EPA initially only
10 allowed a 30-day comment period with no public
11 hearing. The Lung Association was among the
12 organizations who requested 60 additional days and
13 a hearing. We greatly appreciate the additional
14 time and today's public hearing.

15 That additional time is crucial,
16 particularly because EPA has failed to complete a
17 regulatory impact analysis that explains the
18 impacts of the proposal, putting the burden on
19 commenters to do so instead.

20 EPA ignored another important opportunity
21 for review when it failed to consult the Agency's
22 own Science Advisory Board. The SAB, which

1 includes appointed members from this
2 administration, voted at its May meeting to
3 request to review the proposal.

4 In a letter to EPA last month, they said
5 that they were only made aware of the rule through
6 the press, and when it was published in the
7 Federal Register. The SAB said unequivocally,
8 quote, "The proposed rule merits review by the
9 Board."

10 We strongly encourage the Agency to move
11 forward with the SAB review of the proposal. To
12 refuse their request to do so would be
13 unprecedented and in direct contradiction of the
14 Agency's stated claim of wanting the best science
15 to inform its decision-making.

16 EPA rushed out this proposal after an
17 inadequate review process, and it shows. The
18 proposal falls short in several key ways. First,
19 EPA fails to provide any evidence that the changes
20 outlined in the rule are needed. EPA's existing
21 approach towards science, with its detailed review
22 and deliberation of the research, is already

1 transparent and has worked well for decades.

2 First, independent science has revealed
3 that studies prior to publication by recognize
4 journals, then independent and EPA staff
5 scientists reviewed them again and question every
6 aspect of the research in depth. And they do
7 these reviews in wide open processes, including
8 publication, public hearings, and comment periods.

9 EPA does not acknowledge the rigor of
10 this process in its proposal. Instead, it
11 attempts to justify this rule by claiming that the
12 Agency is following in the footsteps of scientific
13 journals. But last month as other commenters have
14 noted, several scientific journals issued a joint
15 statement highlighting their concerns with EPA's
16 proposal and pointed out that even though many
17 peer-reviewed publications have recently adopted
18 transparency policies, they are still able to
19 assess and use studies for which the underlying
20 data cannot be made public.

21 Second, EPA fails to define its
22 requirement that studies must be replicable. Does

1 EPA mean that the Agency couldn't consider a study
2 that looked at health impacts of a one-time event,
3 like a major oil spill?

4 The SAB also raised questions about EPA's
5 failure to define this and other terms.

6 Finally, EPA did not explain how the
7 Agency would implement the rule. The proposal
8 offers no process for public hearing, or even
9 consultation with the SAB over implementation.
10 What process would EPA use to review and assess
11 the existing research and revisions? What
12 guidance would the administrator receive to avoid
13 arbitrary decision-making over the fate of this
14 research?

15 And where would the massive staff time
16 and resources the EPA would need for such a
17 massive additional workload come from? What would
18 have to be sacrificed?

19 EPA's rushed process, its inadequate
20 review, its false attempt to claim that its policy
21 is supported by scientific journals, and its many
22 unanswered questions about how the proposal would

1 work, all underscore a core problem with this
2 rule. It would not improve the use of science of
3 EPA. It would not make the Agency's science-based
4 rules more transparent. It would permanently
5 damage EPA's ability to do its job to protect the
6 public.

7 On behalf of the millions of people with
8 lung disease that we serve who will be hurt by the
9 weaker pollution protections that would result
10 from this proposal, we urge EPA to withdraw this
11 rule to censor science. Thank you.

12 MR. ROBBINS: Thank you.

13 MS. HALL: Would Speaker Number 38, Liz
14 Borkowski, and Speaker Number 39, Janice Nolen,
15 come up to the speaker's table. And Speaker
16 Number 40, Albert Donnay, you're already at your
17 seat. Excellent. Also, if Speaker Number 15,
18 Harvey Fernbach, is in the room, you can take a
19 seat at the on-deck chairs. Last call.

20 MS. BORKOWSKI: Thank you for the
21 opportunity to present comments. My name is Liz
22 Borkowski, and I'm the Managing Director of the

1 Jacobs Institute of Women's Health, which is at
2 the Milken Institute School of Public Health at
3 the George Washington University.

4 The Jacobs Institute is concerned about
5 EPA's proposed rule, "Strengthening Transparency
6 in Regulatory Science," due to the harmful impact
7 it would have on women's health and reproductive
8 justice.

9 We urge EPA to withdraw it based both on
10 its detrimental impacts, and on the lack of a
11 demonstrated need for such a rule. EPA has failed
12 to demonstrate that its current processes for
13 considering science and regulation are inadequate.
14 It has not provided examples of any instances in
15 which insufficient transparency has resulted in
16 outcomes contrary to its statutory mandates or
17 executive orders.

18 Given extensive existing procedures used
19 by EPA and the scientific community at large to
20 ensure the quality of research, EPA has failed to
21 make a case that additional public access to data
22 is necessary.

1 The theoretical, but as yet
2 undemonstrated benefits of EPA's proposed rule,
3 must be weighed against the extensive and
4 unequally distributed costs of such an approach.
5 Failing to consider the best available evidence
6 because the underlying data are not publicly
7 available, would result in regulations that fail
8 to sufficiently protect public health. The
9 consequences would fall most severely on sensitive
10 groups not adequately protected by current rules,
11 which include racial and ethnic minorities, those
12 with low socio-economic status, the elderly, and
13 pregnant individuals and their eventual children.

14 My comments provide a few examples
15 related to reproductive health. First,
16 neurotoxicants are of particular concern to
17 pregnant people and the parents of young children.
18 In regulatory activities, to reduce exposure to
19 neurotoxicants, such as lead and methyl mercury,
20 EPA has relied on an extensive body of research.
21 This research includes longitudinal studies of
22 individuals who are exposed in utero or as young

1 children to higher levels of lead or methyl
2 mercury than would typically occur in the U.S.
3 today. It would not be ethical to publicly
4 release data from these studies, and it would not
5 be feasible, particularly for older studies that
6 used incompatible storage media to locate all
7 participants and obtain their permission.

8 EPA's use of research on lead and methyl
9 mercury also has implications for other agencies
10 that address these substances. For instance, the
11 Department of Housing and Urban Development relies
12 on EPA's renovation, repair, and painting rule in
13 its regulation of renovators working in housing
14 units, receiving HUD housing assistance where lead
15 paint is present.

16 EPA calculated the reference dose for
17 methyl mercury that EPA and the Food and Drug
18 Administration used to create guidelines on fish
19 consumption, including recommendations for
20 pregnant and breast-feeding women.

21 It does not appear that EPA has
22 undertaken the required interagency review process

1 to assess the implications of its rule for other
2 agencies.

3 Another neurotoxicant of concern for
4 reproductive health is the pesticide,
5 chlorpyrifos. Researchers followed a cohort of
6 children exposed to this pesticide before the
7 current ban on indoor use and found lower IQ and
8 working memory to be associated with higher levels
9 of prenatal chlorpyrifos exposure.

10 In a rulemaking process regulating
11 agricultural use of chlorpyrifos, EPA requested
12 the underlying data from the Columbia Center for
13 Children's Environmental Health. The response
14 from Columbia University explained that because of
15 the detailed sociodemographic and health-related
16 elements their data set contains, they did not
17 believe they could submit extensive individual-
18 level data to EPA in a way that would ensure
19 participants' confidentiality.

20 Such concerns are not uncommon with the
21 kinds of longitudinal data sets that allow
22 identification of long-term consequences of

1 environmental exposures. Often, the combination
2 of variables used in an analysis provides enough
3 information to identify individual participants
4 and may include sensitive information, such as
5 diagnosis of neurodevelopmental delays.

6 In addition, endocrine disrupting
7 chemicals are of great concern and reproductive
8 health and EPA has regulated some of these, such
9 as PCBs and PBDEs, under the Toxic Substances
10 Control Act.

11 Under reformed TSCA, EPA must make
12 decisions based on the weight of the scientific
13 evidence, but it is not clear how it can do so if
14 studies may be eliminated from consideration
15 because data sets are not publicly available.

16 If EPA moves forward with the rule it has
17 proposed, it will undermine science and regulatory
18 decision-making by making it difficult and
19 potentially impossible to consider the best
20 available science. This will have detrimental
21 impacts on reproductive justice, health equity,
22 and women's health. The Jacobs Institute of

1 Women's Health urges EPA to withdraw this rule.

2 MR. ROBBINS: Thank you.

3 MS. NOLEN: Hi. Thank you. My name is
4 Janice Nolen. It's J-A-N-I-C-E N-O-L-E-N, and I
5 am the National Assistant Vice President for
6 Policy for the American Lung Association.

7 The American Lung Association turns 114
8 years old this year. For more than a century we
9 have fought to save lives for protecting lung
10 health and preventing lung disease. We oppose the
11 proposed rule.

12 Many years ago, in the early 1980s, my
13 mother-in-law asked me to help her recruit
14 participants in a major new study that they were
15 doing. She worked for the American Cancer Society
16 then. They were looking to create a huge database
17 of ordinary Americans would be willing to provide
18 them with confidential information about their
19 health and medical experiences, and would allow
20 them to track those for years to come.

21 I was so pleased that two men from my
22 church choir in Nashville agreed to participate.

1 They completed the forms and other paperwork, and
2 became two of the more than half million
3 participants in the cancer prevention study too.

4 Fast-forward a decade or so and I learned
5 that their data were now part of a landmark study,
6 the American Cancer Society study that revealed
7 the risks to human health from breathing air
8 pollution that I and my colleagues at the lung
9 association were working hard to clean up.

10 Their data and private health and medical
11 information, from hundreds of thousands of others
12 were -- from hundreds of thousands of other
13 people, who were pointing the way, the need to
14 clean up emissions from power plants, from diesel
15 engines and fuels, and many other sources. I
16 never dreamed when my mother-in-law made her first
17 request to me that EPA scientists and other
18 researchers would mark that study as one of two
19 seminal studies that helped reshape our
20 understanding of the health risks from particulate
21 matter air pollution.

22 None of us then would have ever dreamed

1 that the information these two men provided would
2 have helped to identify and underline the threat
3 to human life posed by microscopic particles in
4 the air we breathe.

5 Furthermore, that study and the Harvard
6 Six Cities Study became examples, not only of
7 ground-breaking research, but of how questions
8 about that research can be reviewed and resolved
9 without having to lose the entire study.

10 Unfortunately, that is an example that
11 this proposal clearly fails to understand. These
12 two studies with decades-old patient data and
13 others in the long list of studies that found
14 evidence of harm from industrial emissions are
15 unique events that no one hopes to replicate, like
16 gulf oil spills, clearly appear to be targets of
17 this proposed rule.

18 Studies that have been -- long been
19 targets of industry polluters and their allies,
20 remains so in this proposal.

21 Once published, these studies raised
22 alarms in the public health community about the

1 increased likelihood of premature death from
2 particulate matter, widespread in the nation. The
3 studies raised alarms within industry too, about
4 the increased likelihood that their polluting
5 sources would have to clean up their emissions.
6 Industry kicked in messaging developed by the
7 tobacco industry, to challenge the science using
8 the same arguments we have in this proposal.

9 I have in my office, a page from a 1999
10 U.S. News and World Report article on the
11 challenges to these studies that could have been
12 written this year.

13 Scientists are working to become more
14 transparent in their research. More researchers
15 use publicly available information, but some
16 studies cover populations that are so limited in
17 size or specialized in their characteristics that
18 these data could not be posted on the web for all
19 the world to see. Anyone who has an account on
20 Facebook should have a visceral knowledge of how
21 important keeping confidential data confidential
22 can be.

1 Meanwhile, EPA could readily review
2 historical data and studies in ways that respect
3 patient confidentiality and the gifts of data from
4 people like my two choir member friends.

5 So far, EPA has failed to show any reason
6 that these changes are needed in the current
7 system. Failed in its own transparency on this
8 issue, in fact since EPA has not sought SAB review
9 of this, and has not provided sufficient rationale
10 for why EPA needs this change, much less how they
11 would this rule going forward.

12 We request EPA to withdraw this proposal.
13 Thank you.

14 MR. ROBBINS: Thank you.

15 MS. HALL: Would Speaker Number 40,
16 Albert Donnay, come to the speaker's table. And
17 Speaker Number 41, Mona Sarfaty.

18 MR. DONNAY: Thank you. My name is
19 Albert Donnay. My comments are based on
20 experience gained from 40 years working on
21 regulatory science as an environmental health
22 engineer and toxicologist, as a research

1 scientist, public health activist, clinician,
2 consultant, peer-reviewer for academic journals,
3 environmental groups and government agencies at
4 all levels, including EPA.

5 I'm glad I get to follow the last two
6 speakers because I want to highlight that although
7 EPA's proposal to "Strengthen Transparency in
8 Regulatory Science" is needed, did not give any
9 examples of regulations that had been undermined
10 by a lack of such transparency.

11 I want to remind everyone here what's at
12 stake and what happened the first time EPA,
13 congress, and environmental groups had to decide
14 whether it was okay to base regulatory standards
15 on published scientific studies whose achieves
16 were no longer available for review.

17 They got the answer right then, and I
18 hope they'll get it right again now. It was May,
19 1983, 35 years ago, and the EPA was about to
20 publish a new national ambient air quality
21 standard for carbon monoxide based on nine studies
22 by a distinguished cardiologist at the VA, Dr.

1 Aronow. When the Washington Post reported that
2 he'd been barred by FDA a year earlier for
3 submitting a wave of false medical experiments
4 after he admitted, quote, "fudging his lab reports
5 in human drug studies."

6 Although EPA's head of the Office of Air
7 Quality Planning and Standards said the Agency
8 had, quote, "No reason to believe anything was
9 wrong with Aronow's CO studies," whose data Aronow
10 claimed at the time, "are excellent and can't be
11 questioned." EPA nevertheless appointed a special
12 team of agency and outside scientists to review
13 his work, quote, "When we read that Aronow had
14 done some kooky things."

15 A month later, The Post reported the
16 shocking results under the headline, "EPA Probe
17 Criticizes a Study Used in Air-Quality Standard."
18 The team had said, quote, "Could not resolve the
19 issue of possible falsification of data because,"
20 quote, "no data were available." Aronow told them
21 he'd discarded the archives of all of his CO
22 studies after first storing them in his garage for

1 years, and offering it to EPA because they didn't
2 want it.

3 The investigators noted considerable
4 concerns about the validity of the results
5 reported, quote, "Raw data were lost or discarded.
6 Adequate records were not maintained, available
7 data were of poor quality, and quality control was
8 nonexistent."

9 And Aronow's published results were
10 consistently too good to be true. They found it,
11 quote, "Rather remarkable that in 10 years of
12 research his papers showed," quote, "not even one
13 missing data point." They concluded that EPA,
14 quote, "Cannot rely on Aronow's data due to the
15 concerns we've noted." And they recommended the
16 Agency commission new research to attempt to
17 replicate Aronow's findings.

18 Congressional hearings and the GAO
19 investigation followed, after which Administrator
20 Ruckelshaus agreed that EPA would not rely on any
21 of Aronow's studies in future rulemakings, but
22 only on studies whose archives were still

1 available for review.

2 In coordination with the California Air
3 Resources Board and the Health Effects Institute,
4 EPA commissioned a series of new controlled human
5 exposure studies on CO, and since 1994, has based
6 the CO NAAQS exclusively on just six of them, all
7 of which published their individual results in
8 deidentified form so they would be available for
9 public review in perpetuity.

10 And it's a good thing they did since all
11 the larger archives of these studies were
12 eventually discarded by their authors without
13 being offered to EPA. This history shows that EPA
14 can and should base regulations solely on studies
15 whose methods and data are available for review.
16 To base regulations on studies that can't be
17 reanalyzed is not science, and there is no need
18 for it. Even federal rules that are based on
19 older epi studies, like the last particulate NAAQS
20 rule in 2013 that cited just six studies could and
21 should be based on more recent research that
22 better reflects current air quality.

1 Over 500 studies a year are now published
2 on particulate epidemiology, and many are in high
3 quality journals that require authors at least to
4 make all their deidentified data and methods
5 available to reviewers, if not to all readers from
6 the posting of supplemental material.

7 Given EPA's interest in basing
8 regulations on more transparent research, EPA
9 should start requiring all the researches it
10 funds, intermural and extramural, to publish their
11 results in such journals. Hopefully this will
12 prompt less rigorous journals that don't require
13 the posting of supplemental material to update
14 their policies.

15 In conclusion, the Aronow scandal shows
16 EPA cannot rely exclusively on traditional peer
17 review to detect misconduct. Aronow reviewers at
18 11 leading journals, as well as EPA staff and
19 their scientific advisors on the CASAC, who also
20 review the studies before recommending that nine
21 be cited as the basis for the CO NAAQS.
22 Unfortunately, despite all this publicity, none of

1 Aronow's studies were retracted, and the EPA has
2 started citing them again, most recently in the
3 2010 integrated science assessment of the CO
4 literature.

5 EPA's proposal to strengthen transparency
6 and regulatory science could stop this from
7 happening again, which is why I support it and
8 encourage my colleagues to do so as well. Thank
9 you.

10 MR. ROBBINS: Thank you.

11 MS. SARFATY: Can you hear me?

12 MR. ROBBINS: Yes.

13 MS. SARFATY: Yeah. Okay. Respected EPA
14 panelists and fellow citizens, my name is Mona
15 Sarfaty. I'm a physician trained in family
16 medicine and public health. I practice primary
17 care medicine and taught medical and public health
18 students in three different academic medical
19 centers for 35 years.

20 Today I direct a program in climate and
21 health at George Mason University in Fairfax,
22 Virginia. I also direct a consortium of physician

1 societies called the Medical Society Consortium on
2 Climate and Health, whose 550,000 members are more
3 than half the physicians in the United States.

4 The Consortium seeks to inform the public
5 and policy makers about the health harms of
6 climate change, and the health benefits of climate
7 solutions. I'm submitting the formal comment of
8 the consortium in written form in a separate
9 document.

10 The EPA is proposing to change the rules
11 that dictate what evidence must be considered as
12 the basis for protecting the public's health. As
13 a physician who spent a summer in Southern
14 California during college and didn't see Mount
15 Wilson looming in front of me for an entire week
16 because of smog, I am incredulous.

17 I remember well the pain in my chest when
18 trying to play tennis on those smoggy days. This
19 was the early 70s, when a republican president was
20 creating the EPA. Now, 50 years hence, tremendous
21 evidence has accumulated that validates my
22 symptoms and the negative effect that unhealthy

1 hair -- air, has on people who must breathe it.

2 After that summer, as a practicing
3 physician, I took care of people with asthma and
4 chronic lung disease who were at greater risk on
5 bad air days. So it is shocking to me that the
6 EPA would propose putting aside huge amounts of
7 thoroughly reviewed evidence on the causal
8 connections between air pollution and poor health,
9 claiming that the basis for this conclusion was
10 secret.

11 Today, I lead a consortium comprised of
12 the country's largest medical societies whose
13 doctor members are highly concerned about the
14 health harms of climate change. The similarities
15 between the current EPA willingness to disregard
16 established science about the connection between
17 carbon dioxide and global warming, and the
18 willingness to disregard solid evidence about the
19 impact of air pollution on health, are glaring.

20 Despite overlapping evidence from every
21 country in the world, and the entire U.S. climate
22 science enterprise, not to mention major federal

1 agencies like NOAA and NASA, the EPA leadership
2 does not accept or recognize reality.

3 To all of us whose lives are dedicated to
4 helping people get and stay healthy, there is a
5 secret lurking in the science of air pollution and
6 global warming. It is not what we have long-known
7 about how burning fossil fuels creates waste
8 products that damage and inflame our lungs. This
9 has been validated by voluminous overlapping
10 research studies. The secret is not that carbon
11 emissions from burning fossil fuels are warming
12 our climate, exacerbating the health harms of air
13 pollution, and causing other dangers to our
14 health, from heat waves, wild fires, pollen, and
15 storms.

16 The secret is hiding in plain sight.
17 Fighting air pollution is the greatest public
18 health opportunity of our time. It's the greatest
19 public health opportunity of our time.

20 Reducing polluting fumes and emissions
21 from fossil fuels will rapidly improve our health
22 and fight climate change.

1 When an EPA's not so secret agenda is to
2 promote fossil fuels, two things follow. The fact
3 that fossil fuels are the major contributor to
4 both air pollution and global warming must be
5 undermined or denied. And the research that
6 documents this reality and how it harms our health
7 must be attacked. It's not hard to see that the
8 approach is to mislead people by wrapping these
9 attacks in rhetoric that's alternatively scary as
10 in secret science, and high-minded, as in
11 transparency.

12 We're told that the rationale for the new
13 proposed strengthening transparency standard is
14 that individual and medical records included in
15 research were secret. In fact, like all medical
16 records, they were confidential and they remain
17 so.

18 The record shows that the same argument
19 of secrecy against scientific studies has been
20 used by polluting industries going back many
21 years.

22 Health providers know that the facts may

1 be scary when our health is threatened. But we
2 also know that denying or ignoring facts blinds us
3 to discovering and acting on the best ways to heal
4 medical problems and protect our health. We can't
5 let that happen. The EPA must live up to its
6 charge and work to face facts and protect our
7 environment and our health. With this proposed
8 regulation, its leadership is pointing in the
9 opposite direction. Thank you.

10 MR. ROBBINS: Thank you.

11 Okay. We're going to take a short recess
12 now and we'll resume at noon.

13 [Morning session adjourned.] [On the
14 record 12:00 p.m., Afternoon session.]

15 MS. RADZIKOWSKI: Good afternoon. If everyone
16 will please take their seats? Hello, and thank
17 you for coming. My name is Mary Ellen Radzikowski
18 and I am in the EPA's Office of Research and
19 Development and I'm one of the hearing officials.
20 Joining me is Lynn Flowers, also from the Office
21 of Research and Development and we have a number
22 of folks: Nanishka Albaladejo, Lauren Hall and

1 Lesley Stobert from SC&A Inc., helping with
2 logistics.
3 The purpose of today's hearing is to accept public
4 comments on the EPA proposed rule, "Strengthening
5 Transparency in Regulatory Science". EPA is
6 accepting comments on all aspects of the proposed
7 regulation. This public hearing is a formal legal
8 proceeding and the testimonies will become part of
9 the administrative record on which EPA will base
10 its decision.
11 Public notice of this hearing was published in the
12 Federal Register on April 30, 2018 (83 FR 18768).
13 EPA is proposing this rule under the authority of
14 5 U.S.C. 301, in addition to the authorities
15 listed in the proposed rule document dated April
16 30, 2018.
17 My role is to ensure that the EPA receives your
18 comments in an orderly fashion. Although EPA
19 panel members here may ask clarifying questions,
20 the intent of the hearing is to listen to your
21 comments, not to discuss or debate the proposal.
22 Now I will go through a few housekeeping items and

1 ground rules: Please refrain from interrupting
2 speakers or asking questions. Shouting,
3 noisemaking or any disruptive conduct which
4 prevents speakers or hearing officials from being
5 heard are not permitted. Please listen quietly so
6 that we can hear each testimony and to ensure that
7 the court reporter is able to record comments
8 accurately and listeners on the phone hear the
9 oral testimonies. For everyone's awareness, this
10 hearing is open to the press and we may have
11 members of the media present with us today. This
12 event is also open to any form of recording,
13 video, audio and photos. We ask that you not
14 cause any disruption to those testifying or
15 observing the hearing.

16 There is no formal lunch break scheduled. You may
17 leave and return to the hearing. Please note that
18 you will need to clear security again so please be
19 aware of the time.

20 If you would like to make an oral comment at
21 today's hearing and did not pre-register to speak,
22 please see the hearing staff at the registration

1 table located right outside the doors here. If
2 you would like to provide a written comment for
3 the official record, you may hand-submit it to EPA
4 staff today, or mail, fax or email your comments.
5 See the staff at the registration table for
6 instructions on how to do that. There is a
7 comment box at the registration table where you
8 can leave hardcopies of your oral testimony or
9 written comments. All comments received will be
10 included in the official docket. If you submit
11 written comments, it is not necessary for you to
12 give the same comments orally; written comments
13 and oral testimonies will receive equal
14 consideration by EPA in preparing its final
15 rulemaking decision.
16 EPA has extended the comment period. Written
17 comments must now be received on or before August
18 16, 2018. EPA will only consider comments related
19 to the proposed rule, "Strengthening Transparency
20 in Regulatory Science", so please refrain from
21 making comments that are not related to this
22 action.

1 EPA will not be providing responses during the
2 hearing. Rather, EPA will prepare a written
3 summary of the comments received that includes
4 responses.

5 The summary of the Response to Comments, the
6 document, will be available at the time EPA issues
7 its final decision. EPA will not make a final
8 decision until all comments submitted during the
9 public comment period have been considered.

10 The hearing is being recorded by a court reporter,
11 who will be preparing a verbatim record of this
12 hearing.

13 Please speak clearly and slowly into the
14 microphone so that the court reporter can
15 accurately record your comments. A copy of the
16 transcript will be placed in the docket. This
17 hearing is also being audio streamed through Adobe
18 Connect via the telephones.

19 The hearing is scheduled -- started at 8 AM this
20 morning and is scheduled to go to 8 PM. We're in
21 the second session: 12pm-4pm.

22 Public restrooms are located down both sides of

1 the hall. At the doors we have staff that can
2 escort you out and back. Please note the location
3 of the emergency exits. Please take a moment to
4 silence your cell phones.

5 Speakers should have been given a sticker upon
6 check-in that lists your assigned session. If you
7 plan to speak and have not received a sticker,
8 please be sure to check in at the registration
9 table. For this session, the speaker sticker
10 color is white, so if you have a white sticker
11 you're registered for this session.

12 Speakers will be called to the speakers' table
13 (located right over there) in pairs by their
14 speaker number.

15 When it is your turn to speak, please come to the
16 table, state and slowly spell your name for the
17 record, and if you are appearing on behalf of
18 someone or another organization. If you are not
19 in the room when it is your turn to speak, I will
20 recall you after all other speakers have made
21 their oral comments. Each speaker will be
22 allotted 5 minutes for remarks. Elected and

1 appointed government officials may be provided
2 additional time, since they represent large groups
3 of constituents. Speakers will be notified when
4 their time has ended. Our timekeeping system
5 consists of green, yellow, and red lights. When
6 you begin to speak, the green light will come on
7 to indicate you have your 5 minutes. The yellow
8 light indicates that you have 1-minute left and
9 when the red appears, your 5 minutes are over. At
10 that moment, if needed, I will politely interrupt
11 you and ask you to wrap-up your testimony to give
12 others an opportunity to speak.

13 At this time, we are going to begin.

14 MS. STOBERT: If Speakers Numbers 1, Pamela
15 Miller, and 2, Elizabeth Geltman, will come to the
16 speakers table and Speakers 3 and 4, Patricia
17 Koman and Alexis Adiman would go to the on-deck
18 seating located near the stage.

19 MS. MILLER: Good afternoon, my name is Pamela
20 Miller, P-A-M-E-L-A, M-I-L-L-E-R. I serve as
21 Executive Director and provide these comments on
22 behalf of Alaska Community Action on Toxics.

1 We're a nonprofit, public interest environmental
2 health, research and advocacy organization,
3 dedicated to protecting public health. I also
4 serve as principle investigator of multiyear
5 research studies involving several universities
6 that investigate exposures and health outcomes
7 concerning endocrine-disrupting chemicals in
8 collaboration with Arctic indigenous communities
9 in Alaska. I traveled the distance to Washington,
10 D.C., from St. Lawrence Island, Alaska, in the
11 Northern Bering Sea, two full days of travel,
12 where we are conducting summer field research and
13 interrupted this because EPA did not make it
14 possible to provide remote testimony.
15 Through a process known as global distillation,
16 the Arctic has become a hemispheric sink for
17 contaminants that are carried on atmospheric and
18 oceanic currents into the north where they
19 concentrate in the bodies of fish, wildlife and
20 people. Indigenous peoples of the Arctic are
21 among the most highly exposed populations on Earth
22 to persistent bio-cumulative and toxic chemicals

1 because of their reliance on traditional foods
2 including fish and marine mammals that they use
3 for their spiritual, cultural and physical
4 sustenance. The communities that I work with on
5 St. Lawrence Island also have higher exposures to
6 chemical contaminants from military operations
7 associated with formerly used defense sites. Our
8 research elucidates exposure pathways, body
9 burdens and health outcomes associated with
10 chemicals including PCBs, PBDEs (or polybrominated
11 diphenyl ethers) and other flame retardants and
12 also perfluorinated substances in homes, in air,
13 water, traditional foods and in the blood serum of
14 the Yupik people of St. Lawrence Island. Our
15 studies have shown elevated body burdens as well
16 as disruption of thyroid function associated with
17 these exposures to certain PBDEs and
18 perfluorinated substances. We are now beginning a
19 research study to investigate exposures to PCBs,
20 PBDEs and currently used organophosphate flame
21 retardants in young Yupik children, age 2 to 12,
22 because elders and other community leaders are

1 concerned about possible adverse effects on
2 children's neurodevelopment. They're concerned
3 that chemical exposures might harm the children's
4 abilities to learn the languages, songs and
5 stories that are so vital for the continuance of
6 the culture of Yupik people. Participation is
7 dependent on the trust of confidentiality that
8 they give to us as researchers. Our research team
9 submits each proposal to rigorous review to the
10 National Institute of Environmental Health
11 Sciences. In the process of the research, we
12 submit also to several institutional review boards
13 for approval to collect sensitive and detailed
14 information on health and behavior as well as
15 spatial and demographic data in an ethical manner
16 that protects human subjects. We have published
17 results of our research in 11 peer-reviewed
18 journal articles after receiving approval from the
19 tribal leadership. These findings help inform
20 interventions and policies to reduce burdens of
21 toxic exposures and prevent further harm to public
22 health. These studies are possible only because

1 we guarantee to protect the medical privacy of
2 participants, again dependent on trust of the
3 researchers. We gather detailed information about
4 peoples' health and occupational histories,
5 practices in their homes and communities that
6 might relate to chemical exposures. If the
7 proposed rule were to go into effect, studies such
8 as these would not be considered by EPA when it
9 makes decisions about chemicals and pollutants
10 that are poisoning the people of the Arctic such
11 as decisions to limit the production and use of
12 persistent biocumulative toxics and other
13 chemicals including those regulated under TSCA and
14 FIFRA and in regulations that hold military and
15 industrial polluters responsible for contamination
16 of air, waters and lands under CERCLA, the Clean
17 Air Act and the Clean Water Act. EPA indicates
18 that the proposed rule is intended to strengthen
19 transparency of EPA regulatory science; however,
20 we find this a duplicitous claim. It would favor
21 industry data protected as confidential business
22 information over public peer-reviewed research.

1 We support the best scientific evidence to inform
2 regulatory decisions. However, this rule would
3 have a dangerous counter effect by limiting the
4 science that should be used to inform decisions
5 about public health. Furthermore, we disagree
6 with the agency's conclusions as stated in the
7 proposed rule document that this action does not
8 have tribal implication as specified in the
9 executive order and requiring government to
10 consult with tribes. This rule would
11 disproportionately affect vulnerable populations
12 including American Indian and Alaska Native People
13 and, therefore, is relevant and requires
14 consultation.

15 MS. RADZIKOWSKI: Excuse me, your time is up. We
16 need to be fair to others.

17 MS. MILLER: I'll wrap up to say that we urge EPA
18 to end this rulemaking promptly and we strongly
19 oppose the proposal. Thank you.

20 MS. RADZIKOWSKI: Thank you.

21 MS. GELTMAN: Good afternoon. Thank you for the
22 opportunity to comment on EPA's proposal entitled,

1 "Strengthening Transparency in Regulatory
2 Science." My name is Elizabeth Glass Geltman, G-
3 E-L-T-M-A-N. I am a Professor of Environmental
4 Health Policy at the City University of New York -
5 - the CUNY School of Public Health, located in
6 Harlem. I am the author of 17 books on
7 environmental and natural resources policy, a
8 peer-reviewer of numerous journals and have worked
9 on EPA-regulated matters for over 30 years. I am
10 also the Chair Elect of the Law Section of the
11 American Public Health Association. As a
12 professor, I aim to advance public health by
13 preventing people from getting sick. My efforts
14 address reducing health impacts, and hence
15 controlling health costs, by evaluating chemical
16 and environmental determinants of health.
17 Although EPA's rule aims to establish a clear
18 policy concerning the use of dose-response data
19 and models that underlie pivotal regulatory
20 policy, the rule is, in fact, a continuation of
21 the Trump administration's two for one regulatory
22 reform policy announced in Executive Orders 13771,

1 13777, and 13783. The rule promises, "to change
2 agency culture and practices regarding data access
3 so that scientific justification for regulatory
4 actions is truly available for validation and
5 analysis." However, the new rule, in fact,
6 creates new regulatory hurdles by discounting and
7 precluding consideration of long-standing,
8 established scientific practice. Rather than
9 promoting the transparency of scientific
10 information used to create environmental
11 regulations, the rule will obscure the democratic
12 process, slow the pace of science and progress,
13 and potentially prevent important health data from
14 being considered by U.S. EPA in outlying important
15 environmental policy. Administrative procedure
16 requires the EPA consider data submitted by the
17 public in evaluating regulations. Let's be clear,
18 scientific studies have always been of uneven
19 quality. EPA has a process in place, including
20 use of Scientific Advisory Board testimony and
21 written and oral public notice and comment, using
22 internal and external peer review to evaluate

1 data. Depending on context some studies are given
2 greater weight than others. Some studies are
3 disregarded entirely. It is inappropriate,
4 however, and unlikely unlawful -- and likely to be
5 unlawful -- under the Administrative Procedure
6 Act. For EPA to categorically eliminate certain
7 types of studies, and hence certain types of data,
8 without considering context. But, even more
9 important, eliminating studies, unless all
10 underlying data is made public, is hazardous to
11 human health and the environment. Longitudinal
12 medical and epidemiological studies are often
13 conducted over years, if not decades. Many
14 studies require people who are study subjects to
15 share very, very personal information, often on
16 the legal or ethical condition that private
17 medical information provided will be protected
18 from public view. EPA is not, and has never been,
19 in the regular business of replicating studies.
20 Timing and the cuts in EPA funding make
21 replicating studies as a condition of promulgating
22 regulations an impossibility. EPA has presented

1 no scientific reason to prevent use of human
2 health studies simply because the underlining
3 medical records are not available for public
4 inspection and review. One size fits all rarely
5 works in fashion and it is even more unworkable in
6 science and regulation. It is imperative the EPA
7 allow consideration of all available scientific
8 data pertinent to a proposed environmental rule or
9 regulation including random, controlled human
10 health trials and other epidemiological studies.
11 Eliminating certain classes of human health
12 studies would be like picking NFL players in the
13 draft without allowing any scouting reports or
14 eliminating the minor league in baseball. It
15 doesn't make sense in sports; it makes even less
16 sense when we're safeguarding our nation's air,
17 water and land. For the reasons stated, I
18 respectfully request the EPA withdraw the
19 misleadingly-named rule entitled, "Strengthening
20 Transparency in Regulatory Science." Thank you
21 very much for allowing me to speak. My comments
22 are my own. I'm happy to answer questions and I

1 will submit more detailed comments for the record.
2 MS. RADZIKOWSKI: Thank you.
3 MS. STOBERT: Speaker Number 5 is Alexis Andiman.
4 Also, if Speaker Number 6 could take a seat on the
5 on-deck seating: Sarah Kogel-Smucker. Speaker
6 Number 3, Patricia Koman, and Speaker Number 4,
7 Alexis Andiman.
8 MS. PATRICIA KOMAN: Thank you. My name is
9 Patricia Koman, K-O-M-A-N. I'm an environmental
10 epidemiologist at The University of Michigan
11 School of Public Health. I'm a member of the
12 American Public Health Association, and in my
13 comments I'm representing myself and my colleagues
14 at the University of California at San Francisco
15 Program for Reproductive Health and the
16 Environment. As a scientist who has formerly
17 served at the U.S. EPA and has been significantly
18 involved in analyzing science to create regulation
19 and programs that protect the public's health from
20 diesel and air pollution, I value the importance
21 of open science which includes appropriate data
22 sharing and full reporting of methods. However,

1 U.S. EPA's proposed rule is not consistent with
2 the principles of open science, inappropriately
3 codifies how science should be conducted, and
4 codifies science policy decision in direct
5 conflict with consensus reports from the National
6 Academies of Sciences 2009 and often the enabling
7 environmental statutes such as the Clean Air Act
8 and the amended Toxic Substances Control Act.
9 Therefore, EPA should withdraw this proposed rule
10 immediately. Instead, EPA should focus on
11 implementing existing initiatives and guidelines
12 for improving data sharing and transparency at
13 federal agencies. The proposed rule is
14 inconsistent with medical ethics and existing
15 legal requirements to ensure the privacy and/or
16 confidentiality of human subject data. The rule's
17 requirements for specific types of test methods,
18 defaults, dose response models and/or other
19 analyses are not supported by current science and
20 these provisions should be removed. The rule is
21 counter to mandates in the amended Toxic
22 Substances Control Act, to use the best available

1 science and systematic reviews for chemical
2 evaluations. Specifically, the proposed rule
3 inappropriately codifies particular data analysis
4 approach such as dose response modeling that
5 should be made based on empirical considerations.
6 This proposed rule will lead EPA to utilize
7 inadequate science resulting in inaccurate
8 analysis and, consequently, inadequate public
9 health protections. The proposed rule does not
10 expressly address the issue of how the new
11 procedures will be protective of public health.
12 Alternatively, existing open science guidelines
13 can and should be used to protect public health
14 such as the 2013 memo from the Office of Science
15 and Technology Policy. In addition, protocols and
16 guidelines such as CONSORT, ARRIVE and STROBE do
17 not require public access to all study data and
18 will still improve the scientific basis of
19 evaluating studies and thus promote public health
20 goals.
21 I want to call your attention to especially
22 troublesome provisions of the proposed rule which

1 is not consistent with current scientific practice
2 and why this proposal should be withdrawn. For
3 example, it is not appropriate to require the use
4 of standardized test methods, guideline studies or
5 so-called good laboratory practice studies. These
6 types of studies are not designed to address
7 health effects from low-dose exposures, complex
8 and systematic endocrine effects, behavioral or
9 learning effects, or metabolic changes. In
10 addition, the so-called good laboratory practice
11 and guideline studies are not consistently
12 associated with higher quality research, proper
13 study design or correct statistical analysis.
14 Further, by dictating the model choices without
15 empirical basis the proposed rule sets a dangerous
16 precedent of prescribing how science should be
17 conducted without regard to the data, or
18 hypothesis or peer review. This is especially
19 troublesome for dose response models. Simply
20 using a greater number of models as the proposal
21 preference is unlikely to improve results without
22 considering the models' assumptions and whether

1 they fit the data set, the goals of the analysis,
2 and many other issues. Therefore, giving priority
3 to studies based on the number or range of models
4 used is scientifically inappropriate.
5 Contrary to the proposed rule's statement about
6 growing evidence of nonlinearity in concentration
7 response functions, the body of empirical evidence
8 points to the opposite, that for most chemicals
9 and pollutants there is likely no safe threshold
10 on a population level because of ongoing exposures
11 and preexisting vulnerabilities. The rule
12 mandates reconsidering using a linear no-threshold
13 dose response but the National Academy of Sciences
14 recommends exactly the opposite in considering
15 low-dose effects. "The committee recommends that
16 cancer and non-cancer responses be assumed to be
17 linear as a default." Regarding other defaults, I
18 oppose provisions that mandate reconsideration of
19 established science-based defaults on a case by
20 case basis. This is in direct contradiction to
21 the National Academy of Sciences recommendations.
22 The rule is counter to the mandates in the amended

1 Toxic Substances Control Act to use the best
2 available science and systematic reviews for
3 chemical evaluations. In contrast, this proposed
4 rule will have EPA ignore well-conducted, relevant
5 studies simply because all the data are not
6 publically available and/or may not conform to the
7 rule's invalid assumptions about good laboratory
8 practices and guidelines, studies, and dose
9 response modeling. This is inconsistent with
10 modern science and the TSCA statutory mandates.
11 Further, EPA's risk evaluation framework rules
12 under TSCA mandate the use of systematic review
13 methods. Well conducted systematic reviews
14 consider the entire body of scientific evidence
15 and the quality and strength of all relevant
16 individual studies are considered to reach the
17 overall conclusion.
18 Therefore, for these reasons, and those outlined
19 in my full written comments, I strongly oppose
20 this proposed regulation and recommend that EPA
21 withdraw it immediately. Thank you.
22 MS. RADZIKOWSKI: Thank you.

1 MS. ANDIMAN: Good afternoon, my name is Alexis
2 Andiman, A-N-D-I-M-A-N. I am an Associate
3 Attorney at Earthjustice, the nation's original
4 and largest nonprofit environmental law
5 organization. Earthjustice strongly opposes the
6 proposed rule entitled, "Strengthening
7 Transparency in Regulatory Science." If
8 finalized, this rule would drastically undermine
9 the U.S. Environmental Protection Agency's ability
10 to protect public health and the environment
11 through science-based regulations restricting the
12 presence of chemicals and pollutants in our air,
13 drinking water, food and consumer products. Under
14 the guise of increasing transparency, the proposed
15 rule would authorize EPA to ignore scientific
16 studies that incorporate personal data and other
17 information that researchers cannot practically,
18 legally or ethically disclose. Indeed, EPA admits
19 that the rule would preclude it from considering
20 landmark studies assessing the health consequences
21 including risks to children associated with
22 exposure to particulate matter and lead. This is

1 unnecessary and unacceptable.

2 The proposed rule raises more issues than I can
3 address during five minutes of testimony. In
4 partnership with other environmental and public
5 health organizations, Earthjustice plans to submit
6 extensive written comments detailing our serious
7 concerns about the rule's procedural and
8 substantive defects. Today, I will focus on three
9 key points.

10 First, EPA lacks authority to adopt the proposed
11 rule. Second, the rule would directly conflict
12 with laws that EPA is charged with implementing
13 and enforcing. And finally, the proposed rule
14 would harm the communities of color and low-income
15 communities that are most in need of strong,
16 science-based protections.

17 First, EPA lacks authority to issue the proposed
18 rule: It is axiomatic that administrative
19 agencies may act only pursuant to authority
20 delegated to them by Congress. The Administrative
21 Procedure Act requires that each notice of
22 proposed rulemaking reference the legal authority

1 under which the rule is proposed. EPA failed to
2 identify any meaningful authority for the proposed
3 rule at issue today. In announcing the rule, EPA
4 cited provisions of numerous environmental laws
5 but virtually every provision cited authorizes or
6 directs EPA to undertake research, not to impose
7 unfounded limitations on the research it will take
8 into account. EPA also cited provisions that
9 authorize it to promulgate rules necessary to
10 achieve the goals of these environmental statutes,
11 but ignoring credible scientific evidence is
12 neither necessary nor consistent with the statutes
13 enacted to protect public health and the
14 environment.

15 Second, the proposed rule directly conflicts with
16 numerous laws. Multiple statutes require EPA to
17 ground its decisions in credible science. For
18 instance, the Safe Drinking Water Act directs EPA
19 to rely on the best available, peer-reviewed
20 science and the best available public health
21 information. The Toxic Substances Control Act
22 similarly mandates that EPA consider all

1 reasonably available information and act in a
2 manner consistent with the best available science.
3 At no point do these statutes suggest that the
4 quality of a scientific study depends on the
5 public's ability to access the underlying data.
6 Indeed, as the EPA previously determined, and as
7 the U.S. Court of Appeals for the D.C. Circuit
8 agreed requiring agencies to obtain and publicize
9 the data underlying all studies on which they rely
10 would be impractical and unnecessary.
11 Finally, the proposed rule would harm the
12 communities that are most in need of strong,
13 science-based protections. Decades of scientific
14 research have established that communities of
15 color and low-income communities are
16 disproportionately likely to experience exposure
17 to chemicals and pollutants. This research is
18 also critical to establishing regulatory
19 safeguards that will protect these communities and
20 their environment. Nonetheless, the proposed rule
21 would preclude EPA from considering this research
22 simply because it incorporates personal health

1 information and other non-public data. As a
2 result, the rule would eliminate an important
3 means of understanding and beginning to resolve
4 the harms suffered by over-burdened communities
5 and that's what perpetuates the environmental
6 injustices these communities already face.

7 Earthjustice urges EPA to withdraw the proposed
8 rule without delay. Thank you.

9 MS. RADZIKOWSKI: Thank you.

10 MS. STOBERT: Speaker Number 5, Alexis Andiman, is
11 already seated at the table. She's speaking on
12 behalf of Devon Hall. If speaker Number 6, Sarah
13 Kogel-Smucker would come to the speaking table.
14 If we could have Speaker Number 7, John Doherty
15 and Speaker Number 8, Tricia Sheehan, come to the
16 on-deck seating. Speaker 5.

17 MS. ANDIMAN: Good afternoon. I am reading
18 testimony on behalf of Devon Hall. D-E-V-O-N, H-
19 A-L-L, who was unable to make it today. My name
20 is Devon Hall. I am the Cofounder and Program
21 Manager at the Rural Empowerment Association for
22 Community Health, also known as REACH. On behalf

1 of REACH and the community we serve, I urge the
2 U.S. Environmental Protection Agency to withdraw
3 its proposed rule entitled, "Strengthening
4 Transparency in Regulatory Science." I cofounded
5 REACH in 2002 to address social, economic and
6 environmental inequities in and around Duplin
7 County, North Carolina. Our primary focus is
8 protecting our community from pollution caused by
9 industrial animal operations. North Carolina is a
10 leading producer of swine and poultry. There are
11 nearly 2-1/2 million hogs and pigs and more than
12 16 million chickens and turkeys in Duplin County
13 alone. Together, these animals generate well over
14 2 billion gallons of wet waste and more than
15 190,000 pounds of dirty litter each year. This
16 waste produces an overpowering odor and pollutes
17 our well water, rivers and streams. REACH uses
18 scientific research as a tool to educate and
19 empower our community. Common sense tells you
20 that it's not healthy to breathe air that smells
21 bad enough to make you gag and that makes your
22 nose run and your eyes water. I began to work as

1 a citizen scientist in 2004 because I wanted to
2 understand exactly what I was breathing and how it
3 was likely to affect my body so that I could
4 better protect myself and help my neighbors
5 protect themselves. So far, I have coauthored
6 nine published studies documenting the threats
7 that under-regulated industrial animal operations
8 pose to community health. For example, I
9 contributed to a study showing that kids who
10 attend school downwind of industrial hog
11 operations are exposed to relatively high levels
12 of hydrogen sulfide, putting them at greater risk
13 of symptoms like difficulty breathing and impaired
14 lung function. I also worked on a study finding
15 that children of people who work in industrial hog
16 operations are more likely to carry dangerous,
17 antibiotic-resistant bacteria on their bodies,
18 even though those children likely never set foot
19 in industrial hog operations themselves.
20 REACH has no interest in putting anybody out of
21 business, but we believe it is possible for
22 industrial animal operations to be more

1 environmentally friendly and more community
2 friendly. It is not enough for us to talk about
3 our symptoms and our diminished quality of life.
4 No matter what we say there will always be some
5 people who think we are just complaining or making
6 things up. My neighbors and I want to be part of
7 the science so that we can gather proof about what
8 we're living with on a daily basis. We hope that
9 policy makers will listen to that science which
10 reflects the experiences of real people and begin
11 to make some changes. If adopted the proposed
12 rule would prevent EPA from considering the
13 scientific studies that REACH helps to conduct.
14 We cannot make all of our data publically
15 available because we cannot risk compromising the
16 confidentiality of the people who contribute to
17 our work. Because we live in a rural community it
18 would be relatively easy to identify study
19 participants based on de-identified information
20 like age, sex, occupation and number in
21 households, even if the participants' names were
22 redacted. Simply put, people would not

1 participate in our studies if they knew that the
2 identifying information they shared could become
3 publically available. Even if EPA were to expand
4 on its vague promise to protect confidentiality, I
5 would not trust the government to deliver. Once,
6 I called the North Carolina Department of
7 Environmental Quality to report a permit violation
8 at an industrial animal operation and, even though
9 I asked to remain anonymous, I received a call
10 back directly from the operator I had complained
11 about. The government apologized to me later, but
12 the damage was done. My anonymity had been
13 violated and I felt violated as a result.
14 On another occasion, the North Carolina Pork
15 Council tried to obtain the identities of study
16 participants from Dr. Steve Wing, a researcher who
17 worked closely with our community. Dr. Wing
18 worked hard to protect our trust, but I know that
19 the legal problems he experienced deterred other
20 researchers from studying the health effects of
21 industrial animal operations. EPA's proposed rule
22 might also deter researchers from partnering with

1 communities like ours to study public health
2 impacts because it would dramatically reduce the
3 influence of those studies in agency rulemaking.
4 Contributing to research about a polluting
5 industry is a lot like acting as a police
6 informant. You're providing information that
7 could help to make everyone more safe, but you are
8 putting yourself at risk, too. People who work at
9 industrial animal operations would lose their jobs
10 if their employers knew they were participating in
11 a scientific study. And losing your job is not
12 the only risk. I have been spoken to hard by
13 powerful people who do not like the work I do.
14 And I know people who have been physically and
15 verbally threatened by industry representatives.
16 EPA has investigated this issue and in January
17 2017, it expressed grave concerns about the
18 intimidation we have experienced.
19 I'll wrap up quickly. My first priority is to the
20 people I serve. I will never do anything to
21 violate their trust or put them in danger. If EPA
22 cares about keeping people safe, it should

1 withdraw the proposed rule immediately and instead
2 take steps to support community-based research.

3 Thank you.

4 MS. KOHEL-SMUCKER: Good afternoon, my name is
5 Sarah Kogel-Smucker, Special Assistant Attorney
6 General at the Office of the Attorney General for
7 the District of Columbia. I am commenting on
8 behalf of Karl A. Racine, the Attorney General for
9 the District of Columbia. EPA's proposed rule,
10 "Strengthening Transparency in Regulatory
11 Science," is a solution in search of a problem.
12 Instead of strengthening ways in which EPA can
13 benefit from advances in scientific studies, the
14 proposed rule limits EPA's access to important
15 studies and hampers the development of regulations
16 needed to protect the public health and welfare of
17 the residents of the District of Columbia and the
18 nation. The proposed rule should be withdrawn.
19 In these comments, I will briefly address why the
20 proposed rule limits the use of valid, peer-
21 reviewed scientific studies, violates several
22 environmental statutes and lacks sufficient

1 details to be appropriately evaluated and
2 implemented.
3 First, the proposed rule impedes EPA's decision-
4 making by creating burdensome, and potentially
5 impossible, barriers to the use of certain
6 scientific studies needed to determine the impacts
7 of pollutants and toxic materials on air quality,
8 water quality and human health. The proposed rule
9 requires that EPA's significant regulatory
10 decisions be justified only by studies based on
11 dose response data and models that area available
12 to the public. This requirement limits EPA's
13 ability to rely on otherwise peer-reviewed
14 scientifically valid studies that do not or cannot
15 make their data publically available because of
16 confidentiality concerns. For example, EPA used
17 the landmark Harvard Six Cities study
18 demonstrating a dramatic link between premature
19 mortality and air pollution as part of its
20 justification for key clean air regulation. The
21 study has been rigorously independently peer
22 reviewed but the subjects were promised

1 confidentiality and the data is not public.
2 Studies with confidential data can still be
3 appropriately peer reviewed through the use of
4 confidentiality agreements and subject to rigorous
5 scientific scrutiny over their methods and
6 conclusions. Where cost-effective and appropriate
7 use of open or publically available data should be
8 encouraged. EPA, however, should not provide
9 blanket limits on the use of studies that cannot
10 be made public because they contain confidential
11 health or business information. Scrubbing studies
12 of such information may be impossible while still
13 keeping the study reproducible. The proposed rule
14 may also have important implications for rules
15 subject to periodic update like the Clean Air Act,
16 NAAQS, if EPA can no longer use the same or
17 similar methods that were used to support the
18 existing rules.
19 Second, the proposed rule violates several
20 environmental statutes because it hinders EPA's
21 ability to rely on best available science or most
22 up to date information as they require. The Clean

1 Air Act, Clean Water Act, Safe Drinking Water Act,
2 Toxic Substances Control Act, and Emergency
3 Planning and Community Right-to-Know Act all
4 require certain decisions or regulatory criteria
5 be based on the most up-to-date science. These
6 criteria are described as best available science,
7 latest scientific knowledge and best available
8 public health information. The proposed rule
9 would illegally limit EPA's ability to rely on
10 best available science in violation of these
11 statutes.

12 The nearly 700,000 residents of the District of
13 Columbia rely on EPA to protect their health and
14 environment. While air quality in the District
15 has improved over the last several decades, many
16 residents who face disproportionate exposure risks
17 because of where they live or work still face
18 risks to their health from air pollution. For
19 example, the American Lung Association's "2018
20 State of the Air (sic)" report gave the District a
21 failing grade for the period from 2014 to 2016
22 because of the number of days that the air was

1 unhealthy for vulnerable populations due to high
2 levels of ozone. The District's vulnerable
3 populations, including the estimated 10,415
4 children in the District with asthma, are entitled
5 to protection from unhealthy air. Because people
6 of color and children living in poverty
7 disproportionately suffer from childhood asthma,
8 environmental justice demands that EPA continue to
9 use advances in scientific research to improve air
10 quality through appropriate regulation. EPA
11 should not be artificially hampered in this duty
12 just because the data or models from a high-
13 quality, peer-reviewed study are not publically
14 available.

15 Lastly, the proposed regulations are too vague to
16 be meaningfully evaluated and successfully
17 implemented. For example, it is unclear whether
18 Section 30.7 requires EPA to conduct its own peer
19 review of all pivotal regulatory science and, if
20 so, whether EPA has the capacity or capability to
21 perform those reviews. Likewise, the exemption
22 process does not provide sufficient standards to

1 ensure that the administrator made consistent
2 determinations. For these reasons, the proposed
3 rule should be withdrawn. Subsequent EPA
4 transparency initiatives, if any, should be based
5 on consultation with the National Academy of
6 Sciences and should not restrict EPA's ability to
7 rely on the universe of best available science
8 when promulgating regulations. Thank you for the
9 opportunity to comment today.

10 MS. RADZIKOWSKI: Thank you.

11 MS. STOBERT: If Speaker Number 7, John Doherty,
12 and Speaker Number 8, Trisha Sheehan, would come
13 to the speaker's table. Speaker Number 9, James
14 Duffy, and Speaker Number 10, Erika Rosen, if
15 you'd go to the on-deck seating.

16 MR. DOHERTY: As a retired EPA toxicologist I know
17 the firsthand frustrations of having to deal with
18 epidemiological reports. However, I believe that
19 epidemiological reports are valuable but more,
20 critical, initial review is needed. Today, I hope
21 to present a path forward. The animal studies
22 that I've reviewed are required to support the

1 registration of pesticides follow very strict
2 quality assurance, good laboratory practices and
3 ethics and reporting standards. Multiple layers
4 of primary and secondary reviewers are identified
5 and assigned to review documents to assure quality
6 assurance and transparency. Every force, however,
7 has a mixed bag of standards to my experience for
8 QLT, quality assurance ethics in reporting. They
9 are often accepted at their face value without
10 documentation of independent review. There is no
11 way to verify the procedures or results presented
12 and the EPA reviewers are not identified. This is
13 very unfair to the public. Historically, I would
14 like to mention two situations where more critical
15 initial evaluation would have prevented social and
16 medical problems. The first is the report on the
17 Kallikak family published in 1912 by Henry
18 Goddard. The book was the foundation of eugenics
19 and was well received at first, but very serious
20 social consequences resulted. However, closer
21 examination revealed that much of the interviewing
22 reflected the biases of the interviewers. Goddard

1 later regretted publication of this book. The
2 other is associated with vaccinations and autism
3 that could not be verified. The publisher
4 retracted the original publication; however,
5 within the past two years there is an increase in
6 measles in Minnesota because people feared autism
7 from vaccinations. When the concept of disparity
8 in the views of animal versus epidemiological
9 studies, and the need to provide a more critical
10 initial review the EPA posed, I am proposing an
11 epidemiology peer review consult with the goal of
12 creating a transparent document reflecting a
13 thorough review be established at EPA. The
14 Council will consist of six independent
15 subcommittee and relevant experts as follows:
16 First would be an ethics subcommittee. All
17 aspects of assuring the personal safety and
18 identities of the individuals on the study would
19 be protected. Second is an end-point evaluation.
20 The relevant experts knowledgeable in cancer and
21 rural behavioral, or whatever the condition is,
22 they would discuss the factors like how many

1 people are really needed in a cohort to make a
2 decision. Identify what is known about that
3 particular condition environmental factors or
4 chemicals are known to cause it. The other -- is
5 self-explanatory. Exposure evaluation, statistic
6 evaluation, analytical chemistry and animal
7 toxicity and structure activity correlations.
8 Each subcommittee will articulate why additional
9 data are or are not needed. The Council will
10 consist of qualified individuals from the EPA, FDA
11 or other agencies' consultants as needed. The
12 Council will have considered the reports of the
13 six independent subcommittees and make their
14 recommendations especially with regard to
15 additional data needed to support a transparent
16 regulatory decision.
17 The report of the Council -- the final report of
18 the Council, will append each of the six
19 subcommittee reports as well as any dissenting
20 opinions. The Council owns the decisions and
21 since all responsible individuals will be
22 identified, the report is thus transparent. Thus

1 AP may further review the Council report.
2 In conclusion, controversies associated with
3 epidemiologic reports may not be eliminated by the
4 Council, but the Council should contribute to
5 minimizing these controversies. Thank you.
6 MS. RADZIKOWSKI: Thank you.
7 MS. SHEEHAN: Good afternoon, my name is Trisha
8 Sheehan, S-H-E-E-H-A-N, and I'm representing Moms
9 Clean Air Force. I traveled here today from my
10 home in New Jersey. I'm the National Field
11 Manager for Moms Clean Air Force. We are an
12 organization of over 1 million members from across
13 the country who are fighting every day to protect
14 the health and safety of their children from toxic
15 chemicals, air pollution and dangerous climate
16 change. I am also a mom to three young boys and
17 last week my family and I joined Democratic House
18 Leader, Nancy Pelosi, to share our own story of
19 how my family was impacted from a toxic chemical
20 accident and today I'm here to speak out in
21 opposition to Acting Administrator Andrew
22 Wheeler's attempts to censor science in the name

1 of transparency. Limiting the scientific
2 information the EPA can use to identify public
3 health threats and protect us from pollution is
4 reckless and dangerous. Not only does this
5 proposal compel EPA to subject high-quality
6 research to extreme unnecessary and untenable
7 levels of disclosure, but it also includes
8 loopholes that would allow the administration to
9 exempt industry from having to disclose details of
10 their own studies. American families depend on
11 the EPA and high-quality science to protect
12 families like mine from the impacts of air
13 pollution and toxic chemicals. This proposal puts
14 that protection in jeopardy, placing the health of
15 our children at risk. This proposal is
16 misleading. It would require the EPA to only
17 consider those studies that use public data. This
18 would prevent the EPA from using studies that are
19 based on personal medical data, eliminating some
20 of the most important long-term epidemiological
21 studies that investigate the impacts of pollution
22 on public health. This proposal would

1 significantly limit the research and data the EPA
2 can use to make informed policy decisions under
3 major public health and environmental laws
4 including the Clean Air Act, the Safe Drinking
5 Water Act and the Toxic Substances Control Act.
6 This proposal means that many studies on
7 populations such as the elderly, children and
8 people of color, groups who often suffer
9 disproportionately from pollution, would be
10 excluded from EPA consideration because making the
11 data public could identify the participating
12 individuals. Excluding this important data from
13 consideration means that implementing the proposal
14 could even further exacerbate negative
15 environmental impacts on these and other
16 vulnerable communities. As a mom who has
17 witnessed her children's health deteriorate due to
18 polluted air they were breathing, I know
19 personally what it's like to rely on scientific
20 studies whose data informed us during that
21 horrifying time. On behalf of my family and Moms
22 Clean Air Force's one million members, I strongly

1 urge the EPA to withdraw this dangerous proposal
2 for the health and safety of our children. Thank
3 you.

4 MS. STOBERT: Speaker 9, James Duffy, and Speaker
5 10, Erika Rosen, if you would come to the
6 speaker's table. Speaker 11, Gretchman Goldman,
7 and Speaker 12, Maggie Flaherty, if you would come
8 to the on-deck seating.

9 MR. DUFFY: Good afternoon, my name is J. Duffy.
10 I am an Associate Attorney with Clean Air Task
11 Force. CATF seeks to help safeguard against the
12 worst impacts of climate change by working to
13 categorize the rapid global development and
14 deployment of low carbon energy and other climate-
15 protecting technologies through research and
16 analysis and public advocacy leadership. EPA's
17 proposal at best is a solution in search of a
18 problem. The Agency has failed to identify a need
19 for further review of the already extensively
20 peer-reviewed public health and environmental
21 science it uses in its decision-making, nor has it
22 made the case the underlying health data must be

1 made more public than current statutes and
2 practices allow. The only thing transparent about
3 the proposal is that is an attempt to undermine
4 EPA's ability to use the best available science by
5 placing arbitrary limits on the ability to
6 consider these studies.

7 As a professor who has cited multiple times the
8 proposal recently stated, if this proposal is
9 finalized, science will be practically eliminated
10 from all decision-making processes so that public
11 health and environmental regulation would then
12 depend on opinion and whim. Banning the use of
13 fully peer-reviewed studies because their
14 underlying data must be kept confidential would
15 eliminate the consideration of vital information
16 in critical public health-making decisions. This
17 is not only unnecessary, it also represents a
18 significant shift in decades-long policy without
19 any justification. As the D.C. Circuit has held
20 when considering this exact question, requiring
21 agencies to obtain and publicize the data
22 underlying the studies on which they rely would be

1 impractical and it would be unnecessary. Congress
2 has clearly spoken, moreover, mandating that the
3 agencies must consider all relevant science. It
4 is well understood, and it has been for decades,
5 that many of the most important public health
6 studies are those based on actual patient
7 information. Because that information must be
8 kept highly confidential and because making even
9 some of the patients' details public would allow
10 them to be identified, the information must be
11 kept private. But that does not mean that these
12 studies can't be, or haven't been, verified. For
13 example, the Harvard Six Cities Study linking fine
14 particulate matter and mortality has been
15 exhaustively reanalyzed by independent
16 institutions, including by the researchers under
17 the auspices of the Health Effects Institute.
18 This reanalysis confirmed the study's essential
19 findings while keeping confidential the underlying
20 data. There are already several ways in which the
21 public can access the studies that EPA uses and in
22 some cases their underlying data without the

1 release of confidential information, including
2 through the Freedom of Information Act which
3 provides an avenue to request raw data, including
4 a process to ensure that sensitive data is
5 protected. The proposal puts the EPA in the
6 untenable position of either violating its mandate
7 to consider all relevant science or violating
8 confidentiality laws. Additionally, the proposal
9 is impermissibly scatter-shot, it's vague, it's
10 confusing, it's insufficiently formed to allow for
11 meaningful comment. It seems more like a request
12 for ideas about how to discredit the best
13 available science than for how to make it more
14 accessible. For example, the proposal claims that
15 it is consistent with the Data Quality Act and
16 HIPAA as well as various executive orders, but
17 each of these contain checks on the release of
18 confidential information. In fact, the
19 longstanding OMB guidelines stemming from the Data
20 Quality Act recognizes peer review as the per se
21 marker of objectivity and the Harvard Six Cities
22 Study reanalysis set the gold standard for